Breaking News Instant updates and real-time market news.

CCXI

ChemoCentryx

$7.27

-0.3 (-3.96%)

07:12
10/15/19
10/15
07:12
10/15/19
07:12

ChemoCentryx can rally 110% on positive Advocate results, says JPMorgan

JPMorgan analyst Anupam Rama says shares ChemoCentryx can rally 90%-110% on positive Phase 3 Advocate trial results of avacopan in ANCA-associated vasculitis, expected in Q4. The analyst sees share downside of 45%-80% on negative results. Rama continues to believe that Advocate has a high probability of success and that the totality of data will be key for adoption. He keeps an Overweight rating on ChemoCentryx shares.

CCXI ChemoCentryx
$7.27

-0.3 (-3.96%)

06/06/19
ADAM
06/06/19
NO CHANGE
Target $14
ADAM
Buy
ChemoCentryx price target lowered to $14 from $20 at Canaccord
Canaccord analyst Michelle Gilson lowered her price target on ChemoCentryx to $14 from $20 following the failure of IFX-1 failing to validate the C5a hypothesis in HS. The analyst believes AAV (associated vasculitis) remains a better indication than HS and is central to his buy thesis. Gilson maintained her Buy rating on ChemoCentryx shares.
06/06/19
RAJA
06/06/19
NO CHANGE
Target $17
RAJA
Strong Buy
ChemoCentryx price target lowered to $17 from $24 at Raymond James
Raymond James analyst Steven Seedhouse removed hidradenitis suppurativa from his model for ChemoCentryx (CCXI) after InflaRx (IFRX) reported that its Phase IIb trial for C5a antibody IFX-1 failed, leading him to lower his price target on the shares to $17 from $24. However, he keeps a Strong Buy rating on ChemoCentryx shares and said he would be a buyer amid the weakness, citing Phase 2 data for avacopan in AAV and a near-term Phase 3 data readout for AAV in Q4.
09/12/19
JPMS
09/12/19
UPGRADE
Target $14
JPMS
Overweight
ChemoCentryx upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded ChemoCentryx to Overweight from Neutral with a price target of $14, down from $16. The analyst sees a favorable risk/reward profile at current share levels.
09/12/19
JPMS
09/12/19
UPGRADE
Target $14
JPMS
Overweight
JPMorgan upgrades ChemoCentryx to Overweight ahead of Phase 3 readout
JPMorgan analyst Anupam Rama upgraded ChemoCentryx to Overweight from Neutral with a price target of $14, down from $16. Following a round of key opinion leader and physician discussions, the analyst believes the Phase 3 Advocate study of avacopan in associated vasculitis has a high probability of success. The share pressure dating back to the spring has created a favorable risk/reward scenario for shares of ChemoCentryx ahead of the Phase 3 results, Rama tells investors in a research note. The analyst expects the readout in the mid-to-late Q4 timeframe.

TODAY'S FREE FLY STORIES

ADSK

Autodesk

$165.15

-0.19 (-0.11%)

07:47
11/22/19
11/22
07:47
11/22/19
07:47
Recommendations
Autodesk analyst commentary  »

Autodesk should meet or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 02

    Dec

LOW

Lowe's

$116.96

-0.88 (-0.75%)

, HD

Home Depot

$218.56

-2.28 (-1.03%)

07:43
11/22/19
11/22
07:43
11/22/19
07:43
Recommendations
Lowe's, Home Depot analyst commentary  »

Lowe's price target…

LOW

Lowe's

$116.96

-0.88 (-0.75%)

HD

Home Depot

$218.56

-2.28 (-1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 11

    Dec

  • 25

    Feb

PZZA

Papa John's

$61.47

1.2 (1.99%)

07:42
11/22/19
11/22
07:42
11/22/19
07:42
Recommendations
Papa John's analyst commentary  »

Papa John's checks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

TSLA

Tesla

$354.82

2.49 (0.71%)

07:41
11/22/19
11/22
07:41
11/22/19
07:41
Recommendations
Tesla analyst commentary  »

Tesla pickup unveiled…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRMK

Broadmark Realty Capital

$10.94

-0.02 (-0.18%)

07:40
11/22/19
11/22
07:40
11/22/19
07:40
Initiation
Broadmark Realty Capital initiated  »

Broadmark Realty Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:40
11/22/19
11/22
07:40
11/22/19
07:40
General news
Treasury Market Outlook: bond yields are modestly richer outside of Asia »

Treasury Market Outlook:…

NKSH

National Bankshares

$47.08

1.59 (3.50%)

07:39
11/22/19
11/22
07:39
11/22/19
07:39
Downgrade
National Bankshares rating change  »

National Bankshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRPO

Precipio

$2.03

0.01 (0.50%)

07:37
11/22/19
11/22
07:37
11/22/19
07:37
Initiation
Precipio initiated  »

Precipio initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$288.66

3.68 (1.29%)

07:36
11/22/19
11/22
07:36
11/22/19
07:36
Hot Stocks
Biogen announces results from Phase 3 EVOLVE-MS-2 study »

Biogen announced detailed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

APDN

Applied DNA Sciences

$4.14

(0.00%)

07:35
11/22/19
11/22
07:35
11/22/19
07:35
Upgrade
Applied DNA Sciences rating change  »

Applied DNA Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$126.80

-0.04 (-0.03%)

07:35
11/22/19
11/22
07:35
11/22/19
07:35
Recommendations
Splunk analyst commentary  »

Splunk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

LYFT

Lyft

$46.77

2.92 (6.66%)

07:35
11/22/19
11/22
07:35
11/22/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 09

    Dec

ZM

Zoom Video

$69.91

-1.02 (-1.44%)

07:34
11/22/19
11/22
07:34
11/22/19
07:34
Initiation
Zoom Video initiated  »

Guggenheim starts Zoom…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 16

    Dec

CBWTF

Auxly Cannabis

$0.00

(0.00%)

07:33
11/22/19
11/22
07:33
11/22/19
07:33
Hot Stocks
Auxly says company 'ready to enter' Cannabis 2.0 market on first day of sales »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

, F

Ford

$8.72

-0.005 (-0.06%)

07:32
11/22/19
11/22
07:32
11/22/19
07:32
Recommendations
Tesla, Ford, General Motors analyst commentary  »

Tesla's $39,900…

TSLA

Tesla

F

Ford

$8.72

-0.005 (-0.06%)

GM

General Motors

$34.66

-0.6 (-1.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 09

    Dec

  • 04

    Feb

CTSH

Cognizant

$63.42

-0.09 (-0.14%)

07:32
11/22/19
11/22
07:32
11/22/19
07:32
Downgrade
Cognizant rating change  »

Cognizant downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMSY

HMS Holdings

$29.51

0.52 (1.79%)

07:32
11/22/19
11/22
07:32
11/22/19
07:32
Upgrade
HMS Holdings rating change  »

Guggenheim upgrades HMS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBWTF

Auxly Cannabis

$0.00

(0.00%)

07:31
11/22/19
11/22
07:31
11/22/19
07:31
Earnings
Auxly Cannabis reports Q3 EPS (C$0.03) vs. (C$0.02) last year »

Reports Q3 revenue C$1.6M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXE

Anixter

$85.30

-0.41 (-0.48%)

07:30
11/22/19
11/22
07:30
11/22/19
07:30
Hot Stocks
Anixter, CD&R announce amendment to up merger consideration to $82.50 per share »

As previously announced,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTSH

Cognizant

$63.42

-0.09 (-0.14%)

07:28
11/22/19
11/22
07:28
11/22/19
07:28
Downgrade
Cognizant rating change  »

Cognizant downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBS

Emergent BioSolutions

$52.46

-1.9 (-3.50%)

07:27
11/22/19
11/22
07:27
11/22/19
07:27
Recommendations
Emergent BioSolutions analyst commentary  »

Cantor reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$47.17

1.2 (2.61%)

07:27
11/22/19
11/22
07:27
11/22/19
07:27
Periodicals
Sanofi EVP in charge of strategy leaving by end of month, Reuters says »

Muzammil Mansuri,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

NXRT

NexPoint Residential

$47.61

-0.49 (-1.02%)

07:27
11/22/19
11/22
07:27
11/22/19
07:27
Initiation
NexPoint Residential initiated  »

NexPoint Residential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APLS

Apellis

$28.49

-0.15 (-0.52%)

07:26
11/22/19
11/22
07:26
11/22/19
07:26
Initiation
Apellis initiated  »

Apellis has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

KKR

KKR

$29.07

-0.25 (-0.85%)

07:26
11/22/19
11/22
07:26
11/22/19
07:26
Periodicals
KKR gets halfway in $3B Asia infrastructure fundraising, Reuters says »

According to Reuters, KKR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.